INTERCEPT PHARMACEUTICALS, INC. (NASDAQ:ICPT) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.
On May 4, 2017, Intercept Pharmaceuticals, Inc. (the Company)
announced its results for the three months ended March 31, 2017
and provided other general business updates. A copy of the
Companys press release (the Press Release) containing such
announcement is attached hereto as Exhibit 99.1. The information
in the Press Release is incorporated by reference into this Item
2.02 of this Current Report on Form 8-K.
Except as shall be expressly set forth by specific reference, the
information contained or incorporated by reference in this Item
2.02 shall not be deemed filed for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended, or otherwise subject
to the liabilities under that section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act
of 1933, as amended.
Item 7.01. Regulation FD Disclosure.
On May 4, 2017, the Company announced that it has completed
enrollment of the interim analysis cohort for its Phase 3
REGENERATE trial of obeticholic acid in nonalcoholic
steatohepatitis patients with liver fibrosis.
Except as shall be expressly set forth by specific reference, the
information contained or incorporated by reference in this Item
7.01 shall not be deemed filed for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended, or otherwise subject
to the liabilities under that section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act
of 1933, as amended.
Item 9.01. Financial Statements and Exhibits.
| (d) | Exhibits. |
The following exhibits are filed with this Current Report on Form
8-K:
| Exhibit 99.1 |
Press Release of Intercept Pharmaceuticals, Inc. dated May 4, 2017 |
About INTERCEPT PHARMACEUTICALS, INC. (NASDAQ:ICPT)
Intercept Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions. The Company’s product candidate, obeticholic acid (OCA), is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). The Company is developing OCA for the treatment of liver diseases, such as primary biliary cirrhosis (PBC), non-alcoholic steatoheptitis (NASH), primary sclerosing cholangitis (PCS) and biliary atresia. The Company is also developing other products INT-767 for the treatment of fibrosis and INT-777 for the treatment of type 2 diabetes. INTERCEPT PHARMACEUTICALS, INC. (NASDAQ:ICPT) Recent Trading Information
INTERCEPT PHARMACEUTICALS, INC. (NASDAQ:ICPT) closed its last trading session down -2.42 at 112.72 with 302,896 shares trading hands.
